结合国情,借鉴先进,脚踏实地,稳中求进——阅读《中国高血压防治指南2018年修订版(征求意见稿)》后的一些浅见
|
摘要
<正>自从2017年11月14日美国发布了美国心血管病学会(American College of Cardiology, ACC)/美国心脏协会(American Heart Association, AHA)高血压指南(美国新版指南)~([1])以后,2018年6月欧洲高血压学会(European Society of Hypertension, ESH)/欧洲心血管病学会(European Society of Cardiology, ESC
引文
[1] Whelton PK,Carey RM,Aronow WS,et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention,detection,evaluation,and management of high blood pressure in adults:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J].J Am Coll Cardiol,2018,71(19):e127-248.
[2] Williams B,Mancia G,Spiering W,et al.2018 practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology:ESH/ESC task force for the management of arterial hypertension[J].J Hypertens,2018,36(12):2284-2309.
[3] 全面解读:2018中国高血压防治指南(征求意见稿).中国高血压联盟(CHL)/北京高血压联盟研究所(BHLI)[EB/OL].http://www.bhli.org.cn/channels/index.php?id=272&cid=2609.
[4] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-743.
[5] Wang Z,Chen Z,Zhang L,et al.Statas of hypertension in China:results from the China hypertension survey,2012-2015[J].Circulation,2018:137(22):2344-2356.
[6] 王文.2018中国高血压防治指南研讨热点[EB/OL].http://www.sohu.com/a/239636140_186367.
[7] 王文.5大新增内容,2018中国高血压防治指南抢先看[EB/OL].http://news.medlive.cn/heart/info-progress/show-147108_129.html.
[8] Wang X,Qin X,Demirtas H,et al.Efficacy of folic acid supplementation in styoke prevention:ameta-analysis[J].Lancet,2007,369(9576):1876-1882.
[9] 邓颖芳,王丽丽,田萌萌,等.高同型半胱氨酸血症患者的叶酸缺乏与MTHFR、MTRR基因多态性情况分析[J].中国分子心脏病学杂志,2015,15(5):1463-1465.
[10] 周宪梁,胡爱华,惠汝太.MTHFR基因多态性及血浆同型半胱氨酸水平与脑卒中的关系[J].中华心血管病杂志,1999,27(2):121-123.
[11] Mark SD,Wang W,Fraumeni JF Jr,et al.Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation:the Linxian nutrition intervention trial[J].Am J Epidemiol,1996,143(7):658-664.
[12] 郭艺芳.2015年中国台湾地区高血压管理指南解读[J]中华高血压杂志,2015,23(2):115-116.
[13] Mancia G,Fagard R,Narkiewicz K,et al.2013ESH/ESC guidelines for the management of arterial hypertension:the task force for the management of arterial hypertension of the European Society of Cardiology(ESC)[J].J Hypertens,2013,31(7):1281-1357.
[14] 王文.如何评价新老降压复方制剂[J].中华高血压杂志,2017,25(3):207-212.
[2] Williams B,Mancia G,Spiering W,et al.2018 practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology:ESH/ESC task force for the management of arterial hypertension[J].J Hypertens,2018,36(12):2284-2309.
[3] 全面解读:2018中国高血压防治指南(征求意见稿).中国高血压联盟(CHL)/北京高血压联盟研究所(BHLI)[EB/OL].http://www.bhli.org.cn/channels/index.php?id=272&cid=2609.
[4] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-743.
[5] Wang Z,Chen Z,Zhang L,et al.Statas of hypertension in China:results from the China hypertension survey,2012-2015[J].Circulation,2018:137(22):2344-2356.
[6] 王文.2018中国高血压防治指南研讨热点[EB/OL].http://www.sohu.com/a/239636140_186367.
[7] 王文.5大新增内容,2018中国高血压防治指南抢先看[EB/OL].http://news.medlive.cn/heart/info-progress/show-147108_129.html.
[8] Wang X,Qin X,Demirtas H,et al.Efficacy of folic acid supplementation in styoke prevention:ameta-analysis[J].Lancet,2007,369(9576):1876-1882.
[9] 邓颖芳,王丽丽,田萌萌,等.高同型半胱氨酸血症患者的叶酸缺乏与MTHFR、MTRR基因多态性情况分析[J].中国分子心脏病学杂志,2015,15(5):1463-1465.
[10] 周宪梁,胡爱华,惠汝太.MTHFR基因多态性及血浆同型半胱氨酸水平与脑卒中的关系[J].中华心血管病杂志,1999,27(2):121-123.
[11] Mark SD,Wang W,Fraumeni JF Jr,et al.Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation:the Linxian nutrition intervention trial[J].Am J Epidemiol,1996,143(7):658-664.
[12] 郭艺芳.2015年中国台湾地区高血压管理指南解读[J]中华高血压杂志,2015,23(2):115-116.
[13] Mancia G,Fagard R,Narkiewicz K,et al.2013ESH/ESC guidelines for the management of arterial hypertension:the task force for the management of arterial hypertension of the European Society of Cardiology(ESC)[J].J Hypertens,2013,31(7):1281-1357.
[14] 王文.如何评价新老降压复方制剂[J].中华高血压杂志,2017,25(3):207-212.